Immune Responses to Antigens in Non-infectious Eye Inflammatory Diseases
| Status: | Completed |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 6 - Any |
| Updated: | 7/28/2018 |
| Start Date: | April 7, 2003 |
| End Date: | July 24, 2018 |
Evaluation of Immune Responses to Different Antigens in Non Infectious Ocular Inflammatory Diseases
This study will collect blood samples from patients with non-infectious eye inflammatory
diseases a spectrum of eye disorders that can produce sight-threatening vision loss. The
blood will be analyzed for substances that may provide a better understanding of the nature
of these disorders, possibly leading to improved treatments. Treatment is not offered under
this protocol.
Patients 6 years of age and older with an eye inflammatory disease, including non-infectious
uveitis, ocular cicatricial pemphigoid, non-infectious scleritis, episcleritis, Stevens
Johnson syndrome, Moorens ulcer, peripheral ulcerative keratitis and keratoconjunctivitis
sicca, may be eligible for this study. Patients may or may not currently be participating in
a treatment trial.
Participants will have blood drawn through a needle in an arm vein. More samples may be
collected if patients enrolled in another study are scheduled for additional visits. No more
than 4 teaspoonfuls of blood will be collected at any one time.
diseases a spectrum of eye disorders that can produce sight-threatening vision loss. The
blood will be analyzed for substances that may provide a better understanding of the nature
of these disorders, possibly leading to improved treatments. Treatment is not offered under
this protocol.
Patients 6 years of age and older with an eye inflammatory disease, including non-infectious
uveitis, ocular cicatricial pemphigoid, non-infectious scleritis, episcleritis, Stevens
Johnson syndrome, Moorens ulcer, peripheral ulcerative keratitis and keratoconjunctivitis
sicca, may be eligible for this study. Patients may or may not currently be participating in
a treatment trial.
Participants will have blood drawn through a needle in an arm vein. More samples may be
collected if patients enrolled in another study are scheduled for additional visits. No more
than 4 teaspoonfuls of blood will be collected at any one time.
Ocular inflammatory diseases can lead to visual loss in adults as well as in children. These
conditions are usually characterized by repeated exacerbations and remissions. The underlying
cause of majority of these conditions is not clear even though an autoimmune mechanism has
been implicated. Various studies have reported an altered immunological profile in these
patients. An underlying immune mechanism has been thought to be playing a role in at least
some of the ocular inflammatory diseases. In addition, evidence from literature also suggests
inflammatory disease may be an important mechanism leading to Age related macular
degeneration and Diabetic retinopathy, two leading causes for vision loss. However, very
little is known about the involvement of immune components in these patients.
This protocol proposes to test for proliferative cell mediated and humoral responses against
self-antigens from patients with ocular inflammatory diseases, AMD and diabetic retinopathy.
Patients will be recruited from other ongoing protocols. An attempt would be made to find any
correlation between the clinical disease and the immunological findings. These findings will
not be used for diagnostic nor therapeutic purposes.
conditions are usually characterized by repeated exacerbations and remissions. The underlying
cause of majority of these conditions is not clear even though an autoimmune mechanism has
been implicated. Various studies have reported an altered immunological profile in these
patients. An underlying immune mechanism has been thought to be playing a role in at least
some of the ocular inflammatory diseases. In addition, evidence from literature also suggests
inflammatory disease may be an important mechanism leading to Age related macular
degeneration and Diabetic retinopathy, two leading causes for vision loss. However, very
little is known about the involvement of immune components in these patients.
This protocol proposes to test for proliferative cell mediated and humoral responses against
self-antigens from patients with ocular inflammatory diseases, AMD and diabetic retinopathy.
Patients will be recruited from other ongoing protocols. An attempt would be made to find any
correlation between the clinical disease and the immunological findings. These findings will
not be used for diagnostic nor therapeutic purposes.
- INCLUSION CRITERIA:
1. Participant is 6 years or older.
2. Adult participant is able to understand and sign the informed consent. If the
participant is younger than 18 years of age at enrollment, has a parent or legal
guardian who is able to understand and sign the consent on their behalf. Children
must provide assent.
3. Patients must have a diagnosis of an ocular inflammatory disease, AMD or diabetic
retinopathy.
EXCLUSION CRITERIA:
1. The presence of non-ocular inflammatory disease.
2. Unwilling or unable to provide a blood sample.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Click here to add this to my saved trials
